Cargando…

Triple negative breast cancer: approved treatment options and their mechanisms of action

PURPOSE: Breast cancer, the most prevalent cancer worldwide, consists of 4 main subtypes, namely, Luminal A, Luminal B, HER2-positive, and Triple-negative breast cancer (TNBC). Triple-negative breast tumors, which do not express estrogen, progesterone, and HER2 receptors, account for approximately 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandapati, Aditya, Lukong, Kiven Erique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314854/ https://www.ncbi.nlm.nih.gov/pubmed/35976445 http://dx.doi.org/10.1007/s00432-022-04189-6

Ejemplares similares

Understanding breast cancer – The long and winding road
por: Lukong, Kiven Erique
Publicado: (2017)

Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance
por: Saha, Taniya, et al.
Publicado: (2022)

Seeking a better understanding of the non-receptor tyrosine kinase, SRMS
por: Goel, Raghuveera Kumar, et al.
Publicado: (2023)

Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells
por: Miah, Sayem, et al.
Publicado: (2019)

A Low-Cost Digital Microscope with Real-Time Fluorescent Imaging Capability
por: Hasan, Md. Mehedi, et al.
Publicado: (2016)

Treatment options for patients with triple-negative breast cancer
por: Santana-Davila, Rafael, et al.
Publicado: (2010)

Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects
por: Nwabo Kamdje, Armel Hervé, et al.
Publicado: (2020)

Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)

Management Options in Triple-Negative Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2011)

Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
por: Obidiro, Onyinyechi, et al.
Publicado: (2023)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Global phosphoproteomic analysis identifies SRMS-regulated secondary signaling intermediates
por: Goel, Raghuveera Kumar, et al.
Publicado: (2018)

Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects
por: Nwabo Kamdje, Armel H., et al.
Publicado: (2020)

Estrogen Actions in Triple-Negative Breast Cancer
por: Treeck, Oliver, et al.
Publicado: (2020)

FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition
por: Ogunbolude, Yetunde, et al.
Publicado: (2017)

Simulated Microgravity Reduces Focal Adhesions and Alters Cytoskeleton and Nuclear Positioning Leading to Enhanced Apoptosis via Suppressing FAK/RhoA-Mediated mTORC1/NF-κB and ERK1/2 Pathways
por: Zhao, Tuo, et al.
Publicado: (2018)

Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies
por: Shoaib, Tagyedeen H., et al.
Publicado: (2023)

Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?
por: Klinke, David J
Publicado: (2014)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon, Joëlle, et al.
Publicado: (2016)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer
por: Spínola-Lasso, Elena, et al.
Publicado: (2023)

Biomedicines—Moving Biologic Agents into Approved Treatment Options
por: Cornetta, Kenneth
Publicado: (2013)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms
por: Yeh, Shan-Ju, et al.
Publicado: (2021)

Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation
por: Bagu, Edward T., et al.
Publicado: (2017)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

The advance of adjuvant treatment for triple-negative breast cancer
por: Ge, Jingyu, et al.
Publicado: (2022)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)

The application of exosomes in the treatment of triple-negative breast cancer
por: Weaver, John W., et al.
Publicado: (2022)

Current approaches in treatment of triple-negative breast cancer
por: Wahba, Hanan Ahmed, et al.
Publicado: (2015)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Triple-negative breast cancer: recent treatment advances
por: Bergin, Alice R T, et al.
Publicado: (2019)

Triple-negative breast cancer: is there a treatment on the horizon?
por: Yao, Hui, et al.
Publicado: (2016)

Investigational Drug Treatments for Triple-Negative Breast Cancer
por: Damaskos, Christos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3sd17e6b505s2s6msokua00564